The link between platelet reactivity and arterial thrombosis risk is well-established, yet incorporating the measurement of platelet reactivity into routine clinical practice has proved impossible—until now.
HaemAnalytica has developed a groundbreaking technology that utilizes platelet surface protein expression to identify intrinsic platelet reactivity without the necessity of measuring platelet function.
This patented innovation is being transformed into a point-of-care test (POCT), effectively overcoming a major obstacle in using platelet function as a critical risk factor in clinical pathways.
